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【要約】 
 
 
 
ALK is a direct transcriptional target of MYCN and regulates cell migration and 
invasion in neuroblastoma 
（ALK遺伝子はMYCNタンパク質の転写標的遺伝子であり、神経芽腫の細胞遊走および
浸潤を調節する） 
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Research Summary 
 
Purpose: Neuroblastoma (NBL) is one of the most common extracranial solid tumors 
in children and is originated from the neural crest cells of the developing sympathetic 
nervous system. The genetic feature most consistently associated with treatment failure 
is an amplification of the MYCN proto-oncogene, which is strongly correlated with 
advanced disease. However, the molecular mechanisms how MYCN induces a 
malignant phenotype of the tumor are still unclear. Human Anaplastic lymphoma kinase 
(ALK) has been identified as an oncogene mutated or amplified in NBLs, although, the 
role of wild-type ALK in NBL is still largely unknown. Recently, it has been reported 
that ALK expression is significantly associated with unfavourable NBL. For better 
understanding a molecular event associated with ALK in the pathogenesis of NBL, it is 
necessary to clarify how ALK gene contributes to NBL progression. 
 
Experimental design: RT-PCR/quantitative RT-PCR and Western-blot were performed 
to check mRNA and protein expression, respectively. ALK promoter activity was 
measured by dual luciferase assay. Chromatin Immunoprecipitation (ChIP) assay was 
used to analyze recruitment of MYCN onto the promoter region. WST-8 assay was 
employed to monitor cell proliferation. Cell migration and invasion assays were 
performed to analyze cell motility after ALK expression. 
 
Results: From the analysis of NBL clinical samples, we have found that ALK 
expression is significantly high in MYCN amplified group (n = 126, P < 0.01). 
Consistent with this evidence, the developing tumors with NBL characteristics in 
MYCN-transgenic mice possess a high expression of ALK. We performed cellular 
experiments and found that overexpression of MYCN induced ALK expression and 
siRNA-mediated knockdown of MYCN resulted in the downregulation of ALK 
expression in NBL and non-NBL cell lines. To confirm a possible relationship between 
MYCN and ALK, we employed MYCN-inducible neuroblastoma cells (Tet21/N) derived 
from a parental neuroblastoma cell line, SHEP, and found that tetracycline deprivation 
led to an induction of MYCN in association with a significant increase in the ALK 
expression. In contrast, addition of tetracycline significantly reduced the expression 
levels of MYCN with a concomitant decrease in ALK expression levels, indicating 
MYCN-dependent regulation of ALK expression. We have identified the promoter 
region of ALK, to which MYCN binds, in the upstream of the first exon from –350 to 
+30 bp and Luciferase reporter assay showed that MYCN overexpression enhanced the 
promoter activity of ALK. The site-specific deletion at MYCN binding site of ALK 
promoter region downregulated its promoter activity and ChIP assay indicated that 
MYCN can be recruited onto the ALK promoter region, suggesting that ALK is a direct 
transcriptional target of MYCN transcription factor. Next, we investigated cell growth 
study using NBL cells and showed that overexpression of ALK enhanced cell 
proliferation, whereas siRNA-mediated knockdown of ALK was correlated with an 
inhibition of proliferation. Colony formation assays also revealed that the number of 
ALK-expressing viable clones were higher than vector control cells. To examine 
whether ALK contributes to metastatic activity of NBL cells, we performed wound 
healing assays in NBL and non-NBL cells, and found that ALK expression enhanced 
cell migration. Consistent with these results, Boyden chamber migration and invasion 
assays also showed a significant increase in the number of migrated and invaded cells 
arising from ALK-expressing cells compared with the vector control cells. Moreover, 
these activities of NBL cells were significantly suppressed by knockdown of ALK 
expression. We have further examined an effect of ALK expression in MYCN-induced 
cell migration and found that forced expression of MYCN enhanced cell migration. Of 
interest, the increased migration by MYCN expression was suppressed by 
siRNA-mediated knockdown of ALK, suggesting that the cell migration induced by 
MYCN is at least partly regulated by ALK expression.  
 
Conclusion: Our results suggest that ALK is a direct transcriptional target of 
MYCN and a key molecule for MYCN to exert influence towards oncogenesis. The 
promoter region of ALK gene contains a non-canonical E-box located upstream of the 
transcription initiation site, and MYCN binds onto the promoter region and regulates its 
transcription. Wild-type ALK functions as a modulator of proliferation as well as cell 
migration and invasion. These findings explore the fundamental understanding of ALK 
in order to develop novel therapeutic tools by targeting ALK for aggressive NBL 
treatment. 
 
